Additional file 1 of Prevention of neointimal hyperplasia after coronary artery bypass graft via local delivery of sirolimus and rosuvastatin: network pharmacology and in vivo validation
Creators: name: Ryu, Ji-yeon
name: Jang, Eui Hwa
name: Lee, JiYong
name: Kim, Jung-Hwan
name: Youn, Young-Nam
Publisher: name: figshare
Year: 2024
Subjects: subject: Biochemistry
subject: Medicine
subject: Genetics
subject: FOS: Biological sciences
subject: Molecular Biology
subject: Physiology
subject: Pharmacology
subject: Chemical Sciences not elsewhere classified
subject: Immunology
subject: FOS: Clinical medicine
subject: Biological Sciences not elsewhere classified
subject: Marine Biology
subject: Cancer
subject: Plant Biology

description: Additional file 1: Table S1. Change in body weight over time in both groups. Table S2. Top 10 biological process enrichment analysis of overlapping targets of coronary artery bypass graft and sirolimus involved in neointimal hyperplasia. Table S3. Top 10 cellular component enrichment analysis of overlapping targets of coronary artery bypass graft and sirolimus involved in neointimal hyperplasia. Table S4. Top 10 molecular function enrichment analysis of overlapping targets of coronary artery bypass graft and sirolimus involved in neointimal hyperplasia. Table S5. Top 10 KEGG pathway enrichment analysis of overlapping targets of coronary artery bypass graft and sirolimus involved in neointimal hyperplasia. Table S6. Top 10 biological process enrichment analysis of overlapping targets of coronary artery bypass graft and rosuvastatin involved in neointimal hyperplasia. Table S7. Top 10 cellular component enrichment analysis of overlapping targets of coronary artery bypass graft and rosuvastatin involved in neointimal hyperplasia. Table S8. Top 10 molecular function enrichment analysis of overlapping targets of coronary artery bypass graft and rosuvastatin involved in neointimal hyperplasia. Table S9. Top 10 KEGG pathway enrichment analysis of overlapping targets of coronary artery bypass graft and rosuvastatin involved in neointimal hyperplasia. Table S10. Top 10 biological process enrichment analysis of overlapping targets of coronary artery bypass graft and both drugs involved in neointimal hyperplasia. Table S11. Top 10 cellular component enrichment analysis of overlapping targets of coronary artery bypass graft and both drugs involved in neointimal hyperplasia. Table S12. Top 10 molecular function enrichment analysis of overlapping targets of coronary artery bypass graft and both drugs involved in neointimal hyperplasia. Table S13. Top 10 KEGG pathway enrichment analysis of overlapping targets of coronary artery bypass graft and both drugs involved in neointimal hyperplasia. Table S14. Top 10 significant bottleneck genes ranked by CytoHubba. Fig. S1. Local drug delivery using a localized perivascular drug delivery device. A Diagram of the localized perivascular drug delivery device with sequential release of sirolimus and rosuvastatin. B In vitro test of the local drug delivery device. Fluorescence image of a spot inserted into an agarose gel after use of the localized perivascular drug delivery device. C Optical image and D scanning electron transmission image of the localized perivascular drug delivery device. Fig. S2. In vivo safety assessment of the localized perivascular drug delivery device. A Changes in body weight of the rabbits in each group during the 4-week experiment (n = 3–5/group). B–D Toxicity assessment of the localized perivascular drug delivery device via H&amp;E staining in organs (liver, kidney, and skeletal muscle) of rabbits in the control and SIR + RSV groups. No significant pathological differences were observed between the two groups (scale bars = 100 μm). H&amp;E hematoxylin and eosin, SIR+RSV combination of sirolimus and rosuvastatin. Fig. S3. Effect of the localized perivascular drug delivery device on cell morphology. A and B Transmission electron microscopy sections of rabbit abdominal aortas at both the hyper-acute stage (1 week) and the acute stage (2 weeks) after injury. The aortas were treated with a localized perivascular drug delivery device containing either no drug (control) or SIR+RSV. SIR+RSV combination of sirolimus and rosuvastatin. Fig. S4. Full-length western blot images. A–C Full-length western blot image for Figs. 8A, 9A, and 10A. SIR + RSV, combination of sirolimus and rosuvastatin. IL-6 interleukin 6, TNF-α tumor necrosis factor alpha, IL-1β interleukin 1 beta, STAT3 signal transducer and activator of transcription 3, p-STAT3 phosphorylated STAT3, Akt a protein cloned from the v-akt oncogene of retrovirus AKT8, mTOR mammalian target of rapamycin, p-mTOR phosphorylated mTOR, NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells, MMP matrix metalloproteinase.